Fig. 2: GSDME mediates ORFV-triggered pyroptosis in tumors.
From: Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity
a Immunoblots for the detection of PARP, GSDME-FL, GSDME-N, and cleaved caspase 3 in ORFV or vehicle-treated (12 h) NCI-H226, ACHN, and EMT6 tumor cell lysates. b Immunoblots for GSDME-FL detection in several murine tumor cell lines. c Immunoblots for GSDME-FL detection in three human tumor cell lines. d Immunoblots for the detection of GSDME protein levels in Ctrl and GSDME-depleted EMT6 cells. e LDH release assays were performed in Ctrl or GSDME depletion EMT6 cells after ORFV (MOI = 1) treatment for 16 h (n = 3). f Images acquired by microscopy display changes in EMT6 cell morphology upon ORFV challenge (MOI = 1) with or without GSDME depletion (scale bar: 20 μm). g Immunoblots for the detection of GSDME-FL, GSDME-N, and HMGB1 in ORFV or vehicle-treated human patient tumor samples for 2 days. GAPDH staining was used as the control for GSDME. Coomassie staining is shown as the control for HMGB1. h Immunoblots for the detection of GSDME-FL and GSDME-N in ORFV or vehicle-treated (i.t.) EMT6-bearing mice for 2 days. The above experiments were successfully repeated two to three times, and the results are presented as the mean ± SD.
